Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14733185 | 1.00 | HTT (0.39) | HTTPKMTHRBMEN1MAPT | |
| SCHEMBL14733226 | 0.85 | HTT (0.41) | HTTPKMTHRBMEN1MAPT | |
| SCHEMBL8498943 | 0.83 | MEN1 (0.51) | HTTPKMTHRBMEN1MAPT | |
| SCHEMBL15804698 | 0.83 | MEN1 (0.51) | HTTPKMTHRBMEN1MAPT | |
| SCHEMBL14733163 | 0.83 | MEN1 (0.51) | HTTPKMTHRBMEN1MAPT | |
| SCHEMBL15796686 | 0.80 | S1PR1 (0.46) | — | |
| SCHEMBL8499776 | 0.80 | HTT (0.41) | HTTPKMTHRBMEN1MAPT | |
| SCHEMBL8499794 | 0.80 | HTT (0.41) | HTTPKMTHRBMEN1MAPT | |
| SCHEMBL8499406 | 0.80 | HTT (0.41) | HTTPKMTHRBMEN1MAPT | |
| SCHEMBL9816463 | 0.75 | KDM4E (0.45) | HTTPKMTHRBMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345791-B2 | Ligands for targeting of S1P receptors for in vivo imaging and treatment of diseases | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2016-05-24 | — | — | US | disclosed |
| US-9345791-B2 | Ligands for targeting of S1P receptors for in vivo imaging and treatment of diseases | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2016-05-24 | — | — | US | disclosed |
| US-9345791-B2 | Ligands for targeting of S1P receptors for in vivo imaging and treatment of diseases | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2016-05-24 | — | — | US | disclosed |
| EP-2744776-A1 | NEW LIGANDS FOR TARGETING OF S1P RECEPTORS FOR IN VIVO IMAGING AND TREATMENT OF DISEASES | Westfälische Wilhelms-Universität Münster (DE) | 2014-06-25 | — | — | EP | disclosed |
| US-20140170067-A1 | NEW LIGANDS FOR TARGETING OF S1P RECEPTORS FOR IN VIVO IMAGING AND TREATMENT OF DISEASES | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2014-06-19 | — | — | US | disclosed |
| US-20140170067-A1 | NEW LIGANDS FOR TARGETING OF S1P RECEPTORS FOR IN VIVO IMAGING AND TREATMENT OF DISEASES | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2014-06-19 | — | — | US | disclosed |
| US-20140170067-A1 | NEW LIGANDS FOR TARGETING OF S1P RECEPTORS FOR IN VIVO IMAGING AND TREATMENT OF DISEASES | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2014-06-19 | — | — | US | disclosed |
| EP-2705283-A1 | DIAPHRAGM | Daikin Industries, Ltd. (JP) | 2014-03-12 | — | — | EP | disclosed |
| WO-2013026765-A1 | NEW LIGANDS FOR TARGETING OF S1P RECEPTORS FOR IN VIVO IMAGING AND TREATMENT OF DISEASES | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013026765-A1 | NEW LIGANDS FOR TARGETING OF S1P RECEPTORS FOR IN VIVO IMAGING AND TREATMENT OF DISEASES | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013027783-A1 | DIAPHRAGM | DAIKIN INDUSTRIES, LTD. (JP) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140170067-A1 | NEW LIGANDS FOR TARGETING OF S1P RECEPTORS FOR IN VIVO IMAGING AND TREATMENT OF DISEASES | S1PR1, S1PR5, S1PR2 | HTT 4030/4885PKM 1605/4885THRB 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.